Stability Indicating RP-HPLC Method for Simultaneous Assay of Atoltivimab, Odesivimab and Maftivimab in a Combined Parenteral Dosage form

This study presents a detailed RP-HPLC method for quantifying Atoltivimab (ALT), Maftivimab (MFT), and Odesivimab (ODE) in the Inmazeb injection formulation. Using an Inertsil column and a 50:50 isocratic mobile phase of sodium bisulfate and acetonitrile, the flow rate was maintained at 1.0 ml/min. Detection and quantification were performed simultaneously at 236 nm. Retention times (RT) for ALT, MFT, and ODE were approximately 2.7, 3.9, and 6.2 minutes, respectively, with a linear concentration range of 8.33–25 μg/ml. The Detection limit (LOD) for ALT, MFT, and ODE were 0.050 μg/ml, 0.100 μg/ml, and 0.088 μg/ml, while the limits of quantification (LOQ) were 0.185 μg/ml, 0.333 μg/ml, and 0.293 μg/ml, respectively.